BRAF and colorectal carcinoma: With regard to the prognostic impact of BRAF-mutated CRC, although new chemotherapeutic regimens and targeted drugs (such as anti-epidermal growth factor receptor-EGFR monoclonal antibodies) have been proposed and Food and Drug Administration FDA-approved [140,141], the overall survival (OS) remains poor and depends on the type of the mutation and the MSI status [142,143].